Tumor News and Research

RSS

Bristol-Myers Squibb reports results from brivanib plus sorafenib phase III trial on HCC

Bristol-Myers Squibb Company today reported the result of the phase III BRISK-FL clinical trial of the investigational agent brivanib versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

20 Jul 2012

Researchers identify six genes with driving mutations in melanoma

It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer? None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.

20 Jul 2012

Study helps explain why leukemia occurs more frequently as people age

Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.

20 Jul 2012

Robotic surgery shows promise for local control of OSCC

In individuals with low-risk oropharyngeal squamous cell carcinoma, treatment with transoral robotic surgery alone can result in an excellent rate of local disease control for up to 3 years, report researchers.

19 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

Champions Oncology operating revenues increase to $7.1M for the year ended April 30, 2012

Champions Oncology, Inc., formerly Champions Biotechnology, Inc., engages in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the year ended April 30, 2012.

19 Jul 2012

Complete resection key to preventing recurrence in T4 rectal disease

Achieving clear surgical margins is essential to the successful treatment of multivisceral resections in rectal cancer, a study confirms.

18 Jul 2012

Estrogen may mediate low incidence of HCC in women

Study findings suggest that estrogen may have a suppressive effect on hepatocellular carcinoma, potentially explaining its lower incidence in women.

18 Jul 2012

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.

18 Jul 2012

Limewater combination therapy can reduce root canal endotoxins

Treating root canals with a combination of chlorhexidine gel and calcium hydroxide results in significant reduction of endotoxins and neutralization of cytotoxic effects compared with the gel plus polymyxin B or saline, report Brazilian researchers.

17 Jul 2012

Activating NOTCH and AKT gene may trigger cholangiocarcinoma

A rare type of cancer thought to derive from cells in the bile ducts of the liver may actually develop when one type of liver cell morphs into a totally different type, a process scientists used to consider all but impossible. UCSF researchers triggered this kind of cellular transformation-and caused tumors to form in mice-by activating just two genes.

17 Jul 2012

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

17 Jul 2012

Research reveals how metformin reduces HCC risk

For every year that a patient with diabetes takes metformin, their risk for hepatocellular carcinoma reduces, say the authors of a study that also sheds light on the cellular pathway it uses.

16 Jul 2012

Identification of IL-9 antitumor activity in melanoma

High expression of interleukin -9 in immune cells inhibits growth of melanoma, show study findings suggesting a role for this T-cell cytokine in tumor suppression.

13 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

High-risk HPV may increase chances of second malignancy in oral cancer

The proportion of oral squamous cell carcinoma patients infected with the human papillomavirus could be around a third, with high-risk versions of the virus accounting for almost three-quarters of those affected, indicate Taiwanese study results.

12 Jul 2012

Altered immune function in relatives of schizophrenia patients

Schizophrenia patients and their unaffected first-degree relatives exhibit immune system alterations compared with mentally healthy individuals, researchers report.

12 Jul 2012

US hospitals fail to meet critical esophagectomy benchmark

A study has shown that most US hospitals fail to ensure that surgeons examine at least 15 lymph nodes during esophagectomy for cancer, and are therefore failing to meet guideline recommendations for detecting metastases.

12 Jul 2012

Eisai, Verastem partner for next-generation of small molecule Wnt inhibitors

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced a research collaboration with Eisai for the next-generation of small molecule Wnt inhibitors.

12 Jul 2012

Cellular change also occurs in early-stage lung cancer, say researchers

Cellular change thought to happen only in late-stage cancers to help tumors spread also occurs in early-stage lung cancer as a way to bypass growth controls, say researchers at Mayo Clinic in Florida.

12 Jul 2012